Antimycobacterial therapy for Crohn's disease. Academic Article uri icon

abstract

  • TO THE EDITOR: I read with interest the meta-analysis performed by Borgaonkar et al. on the efficacy of antimycobacterial therapy for Crohn's disease (1). The authors have found that antimycobacterial therapy was effective in maintaining remission achieved by corticosteroids. The possible role of mycobacterial species in the etiology and pathogenesis of Crohn's disease is intriguing, as is the resulting possibility of adding new drug classes to the armamentarium of anti-Crohn's disease agents. The trials cited by the authors have used clofazimine, rifampin, ethambutol, isoniazid, dapsone, rifabutin, and pyrimethamine- sulphadoxine (1). Fluoroquinolones (FQ) currently consist of an important class of antimycobacterial agents (2). Examples include older FQ such as ciprofloxa-

publication date

  • January 1, 2000